Adherence to chronic medication in older populations: application of a common protocol among three European cohorts

Purpose The purpose of this study was to evaluate and compare medication adherence to chronic therapies in older populations across different regions in Europe. Methods This explorative study applied a harmonized method of data extraction and analysis from pharmacy claims databases of three European countries to compare medication adherence at a cross-country level. Data were obtained for the period between January 1, 2010, and December 31, 2011. Patients (aged ≥65 years) who newly initiated to oral antidiabetics, antihyperlipidemics, or antiosteoporotics were identified and followed for over a 12-month period. Main outcome measures were medication adherence (medication possession ratio, [MPR]; implementation) and persistence on index treatment. All country-specific data sets were prepared by employing a common data input model. Outcome measures were calculated for each country and pooled using random effect models. Results In total, 39,186 new users were analyzed. In pooled data from the three countries, suboptimal implementation (MPR <80%) was 52.45% (95% CI: 33.43–70.79) for antihy-perlipidemics, 61.35% (95% CI: 52.83–69.22) for antiosteoporotics, and 30.33% (95% CI: 25.53–35.60) for oral antidiabetics. Similarly, rates of non-persistence (discontinuation) were 55.63% (95% CI: 35.24–74.29) for antihyperlipidemics, 60.24% (95% CI: 45.35–73.46) for antiosteoporotics, and 46.80% (95% CI: 36.40–57.4) for oral antidiabetics. Conclusion Medication adherence was suboptimal with >50% of older people non-adherent to antihyperlipidemics and antiosteoporotics in the three European cohorts. However, the degree of variability in adherence rates among the three countries was high. A harmonized method of data extraction and analysis across health-related database in Europe is useful to compare medication-taking behavior at a cross-country level.

[1]  K. Bennett,et al.  An observational study examining the effect of comorbidity on the rates of persistence and adherence to newly initiated oral anti‐hyperglycaemic agents , 2013, Pharmacoepidemiology and drug safety.

[2]  E. Menditto,et al.  Doctors commitment and long-term effectiveness for cost containment policies: lesson learned from biosimilar drugs , 2015, ClinicoEconomics and outcomes research : CEOR.

[3]  E. Menditto,et al.  Different approaches to the assessment of adherence and persistence with cardiovascular-disease preventive medications , 2017, Current medical research and opinion.

[4]  V. Orlando,et al.  Risk Management and Healthcare Policy Dovepress Economic Evaluation of Screening Programs for Hepatitis C Virus Infection: Evidence from Literature , 2022 .

[5]  Alessandro Monaco,et al.  Interventional tools to improve medication adherence: review of literature , 2015, Patient preference and adherence.

[6]  A. Lippman Adherence to medication. , 2005, The New England journal of medicine.

[7]  E. Menditto,et al.  Persistence With Statins in Primary Prevention of Cardiovascular Disease: Findings From a Cohort of Spanish Workers. , 2018, Revista espanola de cardiologia.

[8]  Kathleen Insel,et al.  Executive function, working memory, and medication adherence among older adults. , 2006, The journals of gerontology. Series B, Psychological sciences and social sciences.

[9]  A. Capaldo,et al.  Osteoporosis drugs in real-world clinical practice: an analysis of persistence , 2013, Aging Clinical and Experimental Research.

[10]  J. Hugtenburg,et al.  Initial phase of chronic medication use; patients' reasons for discontinuation. , 2006, British journal of clinical pharmacology.

[11]  M. Illario,et al.  Self-Assessment of Adherence to Medication: A Case Study in Campania Region Community-Dwelling Population , 2015, Journal of aging research.

[12]  Henrik Stovring,et al.  Can differences in medical drug compliance between European countries be explained by social factors: analyses based on data from the European Social Survey, round 2 , 2009, BMC public health.

[13]  A. Marengoni,et al.  Toward appropriate criteria in medication adherence assessment in older persons: Position Paper , 2016, Aging Clinical and Experimental Research.

[14]  T. Taylor,et al.  Pharmacy Effect on Adherence to Antidiabetic Medications , 2012, Medical care.

[15]  M. Illario,et al.  Prescription Patterns of Antidiabetic Treatment in the Elderly. Results from Southern Italy , 2016, Current diabetes reviews.

[16]  J. Benner,et al.  Comparing Adherence and Persistence Across 6 Chronic Medication Classes , 2009, Journal of managed care pharmacy : JMCP.

[17]  E. Menditto,et al.  Emerging Role of Capecitabine in Gastric Cancer , 2009, Pharmacotherapy.

[18]  F. Taroni,et al.  The Italian health-care system. , 2005, Health economics.

[19]  K. Bennett,et al.  Pharmacoepidemiology resources in Ireland—an introduction to pharmacy claims data , 2017, European Journal of Clinical Pharmacology.

[20]  S. De Geest,et al.  Adherence to Long-Term Therapies: Evidence for Action , 2003, European journal of cardiovascular nursing : journal of the Working Group on Cardiovascular Nursing of the European Society of Cardiology.

[21]  L. Manzoli,et al.  Assessment and potential determinants of compliance and persistence to antiosteoporosis therapy in Italy. , 2014, The American journal of managed care.

[22]  W. Herman,et al.  Determinants of Adherence to Diabetes Medications: Findings From a Large Pharmacy Claims Database , 2015, Diabetes Care.

[23]  D. Altman,et al.  Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.

[24]  K. Chan,et al.  Comparison of Drug Adherence Rates Among Patients with Seven Different Medical Conditions , 2008, Pharmacotherapy.

[25]  Anuja Roy,et al.  Medication compliance and persistence: terminology and definitions. , 2008, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[26]  M. Weinstein,et al.  Long-term persistence in use of statin therapy in elderly patients. , 2002, JAMA.

[27]  F. Napolitano,et al.  Medication adherence among patients with chronic conditions in Italy. , 2016, European journal of public health.

[28]  G. Fico,et al.  Building bridges for innovation in ageing: Synergies between action groups of the EIP on AHA , 2016, The journal of nutrition, health & aging.

[29]  Jerry L. Grenard,et al.  A systematic review of barriers to medication adherence in the elderly: looking beyond cost and regimen complexity. , 2011, The American journal of geriatric pharmacotherapy.

[30]  P. Kardas Patient compliance with antibiotic treatment for respiratory tract infections. , 2002, The Journal of antimicrobial chemotherapy.

[31]  F. Manguso,et al.  Italian translation and cultural adaptation of the communication assessment tool in an outpatient surgical clinic , 2016, BMC Health Services Research.

[32]  M. Illario,et al.  Rates and reasons for lack of persistence with anti-osteoporotic drugs: analysis of the Campania region database. , 2016, Clinical cases in mineral and bone metabolism : the official journal of the Italian Society of Osteoporosis, Mineral Metabolism, and Skeletal Diseases.

[33]  A. Calderón-Larrañaga,et al.  Cohort Profile: The Epidemiology of Chronic Diseases and Multimorbidity. The EpiChron Cohort Study , 2018, International journal of epidemiology.

[34]  Jeffrey K Aronson,et al.  A new taxonomy for describing and defining adherence to medications. , 2012, British journal of clinical pharmacology.

[35]  Kirsten Axelsen,et al.  The effects of prescription drug copayments on statin adherence. , 2006, The American journal of managed care.

[36]  R. Romanelli,et al.  Disparities in adherence to and persistence with antihypertensive regimens: an exploratory analysis from a community-based provider network. , 2012, Journal of the American Society of Hypertension : JASH.

[37]  Przemyslaw Kardas,et al.  Determinants of patient adherence: a review of systematic reviews , 2013, Front. Pharmacol..

[38]  L. Pani,et al.  Scaling up health knowledge at European level requires sharing integrated data: an approach for collection of database specification , 2016, ClinicoEconomics and outcomes research : CEOR.

[39]  V. Atella,et al.  The impact of cost-sharing schemes on drug compliance in Italy: evidence based on quantile regression , 2014, International Journal of Public Health.

[40]  Steven Kahn,et al.  Adherence to Preventive Medications , 2006, Diabetes Care.

[41]  G. Oster,et al.  Compliance with drug therapy for postmenopausal osteoporosis , 2006, Osteoporosis International.

[42]  Patrik Eklund,et al.  Active and Healthy Ageing and Independent Living , 2015, Journal of aging research.

[43]  T. Grimes,et al.  Relative accuracy and availability of an Irish National Database of dispensed medication as a source of medication history information: observational study and retrospective record analysis , 2013, Journal of clinical pharmacy and therapeutics.

[44]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.

[45]  Patrik Eklund,et al.  Active and Healthy Ageing and Independent Living 2016 , 2016, Journal of aging research.